GULP1 in Ovarian Cancer: Expression, Biological Function, and Clinical Significance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• GULP1 acts as an engulfment adapter for apoptotic clearance.
• Its role in ovarian cancer (OVCA) progression and its association with the tumor microenvironment (TME) are largely unknown.

Purpose of the Study:

• To investigate the role of GULP1 in OVCA.
• To analyze its correlation with immune evasion and key signaling pathways.
• To identify potential therapeutic strategies targeting GULP1.

Main Methods:

• Analysis of GULP1 expression and copy number variations (CNVs) in TCGA-OVCA and GEPIA datasets.
• Gene set enrichment analysis (GSEA) and immune infiltration assessment.
• Molecular docking and cellular assays to evaluate drug binding and GULP1 function.

Main Results:

• GULP1 was found to be downregulated in OVCA, correlating with advanced stages and immune evasion.
• GULP1 expression was linked to hypoxia, EMT, angiogenesis, and TGFβ signaling.
• LFM-A13 showed binding affinity to GULP1, and GULP1 modulation affected OVCA cell migration and invasion.

Conclusions:

• GULP1 serves as a novel biomarker for OVCA progression and immune escape.
• Targeting GULP1 with LFM-A13 presents a potential precision therapy strategy for OVCA.
• Further clinical validation is necessary to confirm the efficacy of LFM-A13.